Benznidazole on Track in Progress to IND and NDA Submissions
Apr 06, 2017 12:01 pm UTC| Business
Investigational new drug (IND) application on track to be submitted in May 2017Manufacturing preparations in line to produce tablets, clinical batches producedCompany anticipates filing new drug application (NDA) in first...
Sharecare Named Official Webby Award Honoree In Two Categories
Apr 06, 2017 12:01 pm UTC| Business
ATLANTA, April 06, 2017 -- Sharecare, the digital health company that helps people manage all their health in one place, announced today that it has been honored in the21st Annual Webby Awards in two categories: Best...
Sharecare Named Official Webby Award Honoree In Two Categories
Apr 06, 2017 12:01 pm UTC| Business
ATLANTA, April 06, 2017 -- Sharecare, the digital health company that helps people manage all their health in one place, announced today that it has been honored in the21st Annual Webby Awards in two categories: Best...
Sprott Completes Second Closing of Private Resource Lending LP
Apr 06, 2017 12:01 pm UTC| Business
TORONTO, April 06, 2017 -- Sprott Inc. (“Sprott” or the “Company”) (TSX:SII) today announced that its Sprott Resource Lending Corp. business unit has completed the second closing of its Sprott Private Resource Lending...
Sprott Completes Second Closing of Private Resource Lending LP
Apr 06, 2017 12:01 pm UTC| Business
TORONTO, April 06, 2017 -- Sprott Inc. (“Sprott” or the “Company”) (TSX:SII) today announced that its Sprott Resource Lending Corp. business unit has completed the second closing of its Sprott Private Resource Lending...
AnaptysBio Announces First-In-Human Dosing of ANB019
Apr 06, 2017 12:01 pm UTC| Business
SAN DIEGO, April 06, 2017 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced...
AnaptysBio Announces First-In-Human Dosing of ANB019
Apr 06, 2017 12:01 pm UTC| Business
SAN DIEGO, April 06, 2017 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced...